You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Kidney conditions
  5. Chronic kidney disease

Tolvaptan for treating autosomal dominant polycystic kidney disease

  • Technology appraisal guidance
  • Reference number: TA358
  • Published:  28 October 2015
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Kidney disease (autosomal dominant polycystic) - tolvaptan [ID652]: final appraisal determination document

Kidney disease (autosomal dominant polycystic) - tolvaptan [ID652]: final appraisal determination document Kidney disease (autosomal dominant polycystic) - tolvaptan [ID652]: final appraisal determination document
04 September 2015
(434.79 Kb 6 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 03 September 2015

Back to top